Aurora Cannabis Inc (CVE:ACB) reported that the firm will be hosting a delegation from Australia, headed by the Jaala Pulford. The objective of the travel to Canada, during which this delegation will even meet with federal executives in Ottawa, is knowledge transfer pertaining to the guidelines governing the medicinal cannabis segment, as well as detailed insight into best measures pertaining to production, distribution and cultivation. The visit will offer insights into the factors that have made the Canadian setup, which currently serves around 200,000 patients, so successful.
The Australian delegation will devote an entire day with Aurora officials, visiting both the automated Aurora Sky facility that is under construction and the firm’s current production facility in Alberta, which was Canada’s preliminary purpose-built indoor cannabis grow facility.
Also, the Minister will meet Shaye Anderson, who is Minister of Municipal Affairs of Alberta and MLA for Leduc-Beaumont, and officials showcasing two of Aurora’s strategic associates: Peter Crock, the CEO of Cann Group Limited, the first licensed cannabis firm of Australia, in which Aurora has around 20% stake; and Denis Taschuk, the CEO of Radient Technologies Inc., in which Aurora has a 17% stake.
In the last month, Victoria recorded a hugely considerable milestone in the advancement of the medical cannabis market in Australia with the awarding of the preliminary commercial license to Melbourne-based firm Cann Group.
Ms Pulford added that associations like the one between Cann Group and Aurora will play a major role in establishing top practices and advancing Australia’s newest economic division. Victoria’s involvement in the medical cannabis industry is in its initial phases and they are keen to know out from other, more established industries what some of the challenges and opportunities are.
In the last trading session, the stock price of Aurora gained more than 4% to close the day at $2.47.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies